E913 is a CCR5 antagonist that competes with the binding of antibodies to CCR5 which recognize the C-terminal half of the second extracellular loop (ECL2B) of CCR5. E913 can specifically block the binding of macrophage inflammatory protein-1alpha (MIP-1alpha) to CCR5 (IC50 = 0.002 µM) and MIP-1alpha-elicited cellular Ca2+ mobilization (IC50 = 0.02 µM). E913 inhibits the replication of laboratory and primary R5 HIV-1 strains as well as various multidrug-resistant monocyte/macrophage tropic (R5) HIV-1 (IC50 = 0.03-0.06 µM). E913 can be used for the research of infection, such as HIV-1 infection[1].
Molekulargewicht:
483.64
CAS Nummer:
[342394-93-8]
Formel:
C28H41N3O4
Target-Kategorie:
CCR,HIV
Anwendungsbeschreibung:
MCE Product type: Reference compound1
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
